Results 231 to 240 of about 27,256 (249)

Biocatalytic Asymmetric Synthesis of Chiral Amines from Ketones Applied to Sitagliptin Manufacture

Science, 2010
Jacob M Janey, Jeffrey C Moore
exaly  

Sitagliptin

Reactions Weekly, 2023
openaire   +1 more source

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Lancet Diabetes and Endocrinology,the, 2017
Bo Ahrén
exaly  

Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial

Lancet, The, 2010
Richard E Pratley, Michael Nauck, Timothy S Bailey   +2 more
exaly  

Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial

Lancet, The, 2010
Richard M Bergenstal, Carol H Wysham
exaly  

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

New England Journal of Medicine, 2015
Jennifer B Green, Paul W Armstrong, John Buse   +2 more
exaly  

Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

Lancet Diabetes and Endocrinology,the, 2019
Thomas R Pieber, Anna Mertens, Young Min Cho   +2 more
exaly  

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Hepatology, 2019
Jinhua Yan, Hongyu Kuang, Qin Huang
exaly  

Highly Efficient Asymmetric Synthesis of Sitagliptin

Journal of the American Chemical Society, 2009
Feng Xu, Shane W Krska
exaly  

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

Lancet, The, 2012
Pablo Aschner, Juliana Chung-ngor Chan, David Owens   +2 more
exaly